Managers / Q3 2020 · view latest →
KNOTT DAVID M
CIK 0000808722
Summary
Knott David M reported $170M in U.S.-listed holdings across 135 positions for Q3 2020.
Its largest position, LGND, represents 13.3% of the portfolio.
Compared with Q2 2020, the fund opened 12 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 79.9% · $136M
- Other · 7.6% · $13M
- Ltd Part · 7.0% · $12M
- MLP · 4.7% · $8M
- REIT · 0.6% · $954,000
- Other · 0.1% · $247,000
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| FSICUSDFS KKR Capital Corp. | NEW | +395.2K | 395.2K | +$6M | $6M |
| Vapotherm, Inc. | NEW | +49.0K | 49.0K | +$1M | $1M |
| ALXNAlexion Pharamaceuticals, Inc. | NEW | +12.0K | 12.0K | +$1M | $1M |
| MDWTUSDMidwest Holding Inc. | NEW | +83.3K | 83.3K | +$1M | $1M |
| FGENEURFibroGen, Inc. | NEW | +19.7K | 19.7K | +$811,000 | $811,000 |
| GILDGilead Sciences, Inc. | NEW | +11.0K | 11.0K | +$695,000 | $695,000 |
| iShares Nasdaq Biotechnology ETF | NEW | +1.0K | 1.0K | +$135,000 | $135,000 |
| ALXOALX Oncology. Inc | NEW | +3.0K | 3.0K | +$113,000 | $113,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $275M | 197 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $281M | 195 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $234M | 166 | May 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $221M | 145 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $170M | 135 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $183M | 127 | Aug 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $158M | 156 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $247M | 152 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $238M | 157 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $237M | 148 | Aug 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $251M | 143 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $213M | 133 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- DORSET MANAGEMENT CORP028-10281
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.